News & Updates

Interstitial lung disease (ILD) rarely occurs in patients with systemic lupus erythematosus (SLE), but when it does, ILD is often associated with other systemic autoimmune disorders and may even significantly contribute to mortality, according to a study.

In individuals with immune-mediated inflammatory diseases (IMIDs*), a 2-week interruption in methotrexate (MTX) treatment led to enhanced COVID-19 booster vaccine response compared with those who continued with MTX treatment, according to findings from the VROOM** study.

Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.

Temporarily discontinuing methotrexate treatment for 1 week appears to induce satisfactory response to a seasonal influenza vaccine in patients with rheumatoid arthritis (RA), with a similar effect as a 2-week interruption schedule, according to a study.

Combination therapy with methotrexate (MTX) plus etanercept (ETN) results in more improved outcomes in men than in women with psoriatic arthritis (PsA) for minimal disease activity (MDA) and Psoriatic Arthritis Disease Activity Score (PASDAS), a study has shown.

Psoriatic arthritis (PsA) patients with moderate disease activity (MDA) at baseline who are treated with apremilast are more likely to achieve treatment targets than those with high disease activity (HDA), a recent study has shown.